8-K: ImmunityBio Changes Auditors, Replacing Ernst & Young with Deloitte

ImmunityBio announced the dismissal of Ernst & Young LLP and the appointment of Deloitte & Touche LLP as its new independent registered public accounting firm.

Summary

• ImmunityBio's Audit Committee approved the dismissal of Ernst & Young LLP (EY) as the company's independent registered public accounting firm on March 13, 2025.
• The dismissal was not due to any disagreements regarding accounting principles, financial statement disclosure, or auditing scope.
• EY's reports on the consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain any adverse opinions or disclaimers.
• There were no disagreements or reportable events between ImmunityBio and EY that would have required reference in EY's reports.
• The Audit Committee approved the engagement of Deloitte & Touche LLP (Deloitte) as the company's new independent registered public accounting firm for the fiscal year ending December 31, 2025.
• This appointment is subject to Deloitte's customary client acceptance procedures.
• ImmunityBio did not consult with Deloitte on any matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K during the two most recent fiscal years and the interim period through March 13, 2025.

Sentiment

Score: 6

Explanation: The announcement is neutral, detailing a change in auditors. While not inherently positive or negative, such changes can sometimes raise investor questions, hence the moderate score.

Positives

• The dismissal of EY was not related to any disagreements on accounting principles or practices, financial statement disclosure, or auditing scope or procedure.
• EY's reports on the consolidated financial statements of the Company as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

Industry Context

Changes in auditors are not uncommon, but they can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting. Investors often scrutinize these changes to understand the reasons behind them and assess any potential impact on the company's financial statements.

Comparison to Industry Standards

• Auditor changes are a normal part of corporate governance, with companies like Pfizer, Johnson & Johnson, and Merck also periodically reviewing and changing their auditors.
• The selection of Deloitte, a Big Four accounting firm, aligns with industry standards for companies of ImmunityBio's size and complexity.
• The process of engaging a new auditor typically involves a thorough review of qualifications, independence, and expertise, similar to what ImmunityBio's Audit Committee likely undertook.

Stakeholder Impact

• Shareholders may want to understand the reasons behind the auditor change, although the company states it was not due to disagreements.
• The change could impact the workload and responsibilities of the company's finance and accounting teams.

Key Dates